Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-06 10:52 am Sale |
2025-02-28 | 13G | Revance Therapeutics, Inc. RVNC |
JPMORGAN CHASE & CO JPM |
0 0.000% |
-5,686,631 (Position Closed) |
Filing History |
| 2025-02-13 4:02 pm Sale |
2024-09-30 | 13G | Revance Therapeutics, Inc. RVNC |
Palo Alto Investors LP | 1,611,787 1.540% |
-3,625,497 (-69.22%) |
Filing History |
| 2025-02-11 12:16 pm Purchase |
2024-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
JPMORGAN CHASE & CO JPM |
5,686,631 5.400% |
2,917,940 (+105.39%) |
Filing History |
| 2025-02-06 6:19 pm Purchase |
2025-01-30 | 13G | Revance Therapeutics, Inc. RVNC |
Glazer Capital, LLC | 7,210,121 6.870% |
7,210,121 (New Position) |
Filing History |
| 2025-01-30 09:01 am Unchanged |
2025-01-30 | 13D | Revance Therapeutics, Inc. RVNC |
Teoxane SA | 6,550,800 6.200% |
0 (Unchanged) |
Filing History |
| 2025-01-10 4:52 pm Purchase |
2025-01-02 | 13G | Revance Therapeutics, Inc. RVNC |
Beryl Capital Management LLC | 6,359,570 6.100% |
4,717,122 (+287.20%) |
Filing History |
| 2025-01-06 09:00 am Unchanged |
2025-01-06 | 13D | Revance Therapeutics, Inc. RVNC |
Teoxane SA | 6,550,800 6.200% |
0 (Unchanged) |
Filing History |
| 2024-12-19 09:00 am Unchanged |
2024-12-19 | 13D | Revance Therapeutics, Inc. RVNC |
Teoxane SA | 6,550,800 6.200% |
0 (Unchanged) |
Filing History |
| 2024-10-31 1:20 pm Sale |
2024-09-30 | 13G | Revance Therapeutics, Inc. RVNC |
FRANKLIN RESOURCES INC BEN |
4,784,658 4.600% |
-1,323,619 (-21.67%) |
Filing History |
| 2024-10-23 7:17 pm Sale |
2024-09-30 | 13G | Revance Therapeutics, Inc. RVNC |
GIC Private Ltd | 0 0.000% |
-5,825,881 (Position Closed) |
Filing History |
| 2024-10-07 10:08 am Sale |
2024-10-07 | 13G | Revance Therapeutics, Inc. RVNC |
Capital World Investors | 0 0.000% |
-6,948,769 (Position Closed) |
Filing History |
| 2024-09-16 5:01 pm Purchase |
2024-09-05 | 13G | Revance Therapeutics, Inc. RVNC |
Beryl Capital Management LLC | 1,642,448 1.600% |
1,642,448 (New Position) |
Filing History |
| 2024-09-09 10:40 am Sale |
2024-09-09 | 13G | Revance Therapeutics, Inc. RVNC |
Capital World Investors | 6,948,769 6.600% |
-4,990,307 (-41.80%) |
Filing History |
| 2024-04-09 1:17 pm Sale |
2024-03-29 | 13G | Revance Therapeutics, Inc. RVNC |
JPMORGAN CHASE & CO JPM |
2,768,691 2.600% |
-1,986,080 (-41.77%) |
Filing History |
| 2024-02-14 4:55 pm Sale |
2023-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
Palo Alto Investors LP | 5,237,284 5.960% |
-46,325 (-0.88%) |
Filing History |
| 2024-02-14 3:45 pm Sale |
2023-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
Antara Capital LP | 0 0.000% |
-5,239,600 (Position Closed) |
Filing History |
| 2024-02-13 5:13 pm Purchase |
2023-12-29 | 13G | Revance Therapeutics, Inc. RVNC |
The Vanguard Group | 5,069,625 5.770% |
573,309 (+12.75%) |
Filing History |
| 2024-02-13 09:39 am Sale |
2023-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
Polar Capital Holdings Plc | 3,169,239 3.600% |
-1,679,394 (-34.64%) |
Filing History |
| 2024-02-09 6:21 pm Purchase |
2024-02-07 | 13G | Revance Therapeutics, Inc. RVNC |
Capital World Investors | 11,939,076 13.600% |
2,458,920 (+25.94%) |
Filing History |
| 2024-02-09 10:05 am Purchase |
2023-12-31 | 13G | Revance Therapeutics, Inc. RVNC |
GIC Private Ltd | 5,825,881 6.630% |
332,916 (+6.06%) |
Filing History |